Medical Oncology

Prostate Cancer

Prostate Cancer Medical Oncologists in Melbourne

Prostate cancer is one of the most commonly diagnosed cancers in Australian men. Many prostate cancers grow slowly and can be managed initially with active surveillance or local treatment, while others behave more aggressively or present after spreading beyond the prostate. A medical oncologist becomes particularly important when drug treatment is being considered, including hormone therapy, androgen receptor pathway inhibitors, chemotherapy, targeted therapy or radiopharmaceutical approaches.

Northern Blood & Cancer Care provides specialist medical oncology consultations in Melbourne for men with high-risk, recurrent or advanced prostate cancer, as well as patients seeking an oncology opinion as part of multidisciplinary treatment planning. Our oncologists work with urologists, radiation oncologists, nuclear medicine physicians and other specialists to coordinate care according to stage, imaging, PSA behaviour, pathology and the patient’s general health.

How Common Is Prostate Cancer in Australia?

Prostate cancer is Australia’s most commonly diagnosed cancer. The Australian Institute of Health and Welfare estimated that around 29,000 men would be diagnosed in 2025, representing approximately 30% of cancers diagnosed in Australian males. Many prostate cancers are slow-growing, while others behave more aggressively, so the diagnosis alone does not determine whether or how quickly treatment is required.

Conditions & Treatments

Localised prostate cancer is confined to the prostate, but its risk of recurrence varies according to PSA, grade group/Gleason score, tumour stage and imaging. Low-risk disease may be suitable for active surveillance, while surgery or radiotherapy are common curative-intent treatments for higher-risk disease. Medical oncology input may be considered when systemic treatment is being used alongside radiotherapy or when the disease has very high-risk biological features. Hormone therapy can improve cancer control in selected patients but also has metabolic, bone and sexual side effects that need active management.

After surgery or radiotherapy, a rising PSA can indicate recurrent prostate cancer before disease is visible or symptomatic. The significance depends on the original pathology, PSA doubling time and previous treatment. Modern imaging such as PSMA PET can help localise recurrence in many patients and may identify opportunities for salvage radiotherapy or targeted treatment. For some men, observation remains appropriate; for others, hormone therapy or other systemic treatment is considered based on the risk of progression.

When prostate cancer has spread to other parts of the body but still responds to suppression of testosterone signalling, it is called metastatic hormone-sensitive prostate cancer. Treatment usually begins with androgen deprivation therapy and is commonly intensified with an additional androgen receptor pathway inhibitor and, in selected patients, chemotherapy. The choice depends on disease volume, symptoms, fitness, other conditions and patient preference. Earlier use of combination treatment has changed outcomes substantially compared with hormone therapy alone, making specialist discussion important at the time metastatic disease is first identified.
Prostate cancer can eventually progress despite very low testosterone levels. At this stage, treatment may include different hormonal agents, chemotherapy, PARP inhibitors for cancers with relevant DNA repair alterations, radioligand therapy in appropriately selected PSMA-positive disease, or clinical trials. Treatment sequencing is individualised according to previous therapy, molecular testing, symptoms, sites of disease and bone marrow reserve. The focus remains on cancer control, symptom relief and maintaining function and quality of life.

How We Investigate & Plan Care

Oncology assessment integrates PSA trends, prostate biopsy or prostatectomy pathology and imaging. In advanced disease, genomic testing of tumour tissue or blood may be considered because alterations in genes involved in DNA repair can influence treatment choices. Inherited genetic testing may also be appropriate for some men, particularly with metastatic disease or a strong family history of prostate, breast, ovarian or pancreatic cancers.

Bone health and cardiovascular/metabolic health are important parts of care because long-term androgen deprivation can reduce bone density and contribute to changes in weight, glucose and cardiovascular risk. Baseline assessment, exercise, adequate calcium/vitamin D where appropriate and bone-protective treatment may be discussed.

Treatment & Care

Treatment & Ongoing Care

Treatment is monitored using PSA, symptoms, imaging when needed and routine blood tests. Side-effect management may include strategies for hot flushes, fatigue, sexual health, bone health and loss of muscle mass. Referral to an accredited exercise physiologist can be particularly useful during androgen deprivation therapy to support strength, function and metabolic health.

Northern Blood & Cancer Care’s prostate cancer service brings together medical oncologists with dedicated genitourinary expertise and links to multidisciplinary urology, radiation oncology, nuclear medicine and tertiary cancer services across Melbourne. This allows patients to receive specialist oncology care while remaining connected to the broader services that may be required as treatment changes.

Before You Visit

Preparing for Your Appointment

If you are attending for a new consultation, please bring a current referral, a list of medications and any recent pathology, imaging or biopsy reports that are relevant to this problem. Where possible, serial results are more useful than a single test because they show whether an abnormality is stable, improving or progressing. Your specialist will explain what the results mean, which findings matter, whether additional tests are required and the options available. You are welcome to bring a family member or support person, particularly when the consultation is likely to involve a new diagnosis or a complex treatment decision.

Our Experts

Northern Blood & Cancer Care brings together Melbourne specialists with complementary clinical, hospital and research appointments. The clinicians most closely associated with this service include:

Medical Oncology Expertise

Specialist Oncology for Complex Prostate Cancer

For men with high-risk, recurrent or advanced prostate cancer, treatment choices can become increasingly specialised. Northern Blood & Cancer Care brings together medical oncologists with dedicated genitourinary expertise, including links with the Australian Prostate Centre, prostate cancer research and multidisciplinary services across Melbourne, helping patients navigate systemic treatment and treatment sequencing with an experienced oncology team.

Northern Blood & Cancer Care

Specialist Blood & Cancer Care in Melbourne

Northern Blood & Cancer Care brings together a highly experienced team of haematologists, medical oncologists and specialist physicians, with consultations available at Northern Private Hospital in Epping.

Contact our team to arrange an appointment or discuss a referral.